You are here

Articles

TFR in chronic myeloid leukemia: Lights and shadows. In several studies, NK cell numbers or functional subsets of NK cells were shown to be higher in patients who maintain TFR

published: 26 March 2022

Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission

published: 1 March 2022

Top Vitamin D Research Papers- 2021

published: 23 February 2022

63rd ASH Annual Meeting - CMLAdNet Conference Report

published: 21 February 2022

2021’s Top 10 Blogs from GrassrootsHealth:

published: 30 December 2021

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

published: 30 December 2021

Taming the gatekeeper: ponatinib dose holds the key

published: 3 December 2021

CML Highlights of the 63rd ASH Annual Meeting

published: 24 November 2021

iCMLf : CML Knowledge Centre

published: 7 October 2021

Vit D -The story behind the Beginning of D*action

published: 1 October 2021

Results from ACEMBL Trial - Aciminib vs Bosutinib

published: 7 September 2021

Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?

published: 7 September 2021

Long-term follow-up of lower dose dasatinib (50 mg daily)

published: 3 September 2021

UK patients needed for "MyeloidScan" study – Long COVID in patients with myeloid blood cancers

published: 23 August 2021

A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia

published: 30 June 2021

Successful tyrosine kinase inhibitor discontinuation outsideclinical trials — data from the population-based Swedish CML registry

published: 30 June 2021

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome

published: 16 May 2021

Models of care for chronic myeloid leukemia patients during the COVID‐19 pandemic

published: 14 May 2021

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?

published: 4 February 2021

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib vs bosutinib

published: 26 January 2021